AnaptysBio CEO suddenly exits
To view this email as a web page, click here

Today's Rundown

Featured Story

Moderna trains its mRNA tech on the common cold and a triple whammy against 3 respiratory diseases

Moderna is adding two more vaccine programs to its roster: a combination respiratory candidate and a shot targeting all four endemic human coronaviruses that cause the common cold.

read more

Top Stories

Ex-Biogen R&D chief Al Sandrock lands CEO job at Voyager, taking over the Big Pharma darling in early days of its turnaround strategy

Al Sandrock, M.D., Ph.D., has identified the destination of his post-Biogen voyage. Months after leaving Biogen in the wake of the Aduhelm debacle, Sandrock has taken up the CEO position at Voyager Therapeutics, putting him in charge of a next-generation gene therapy play that has been attracting Big Pharma interest.

read more

After going 0 for 2, AnaptysBio CEO makes immediate exit, leaving a strategic portfolio review in his wake

Back-to-back failures have spurred AnaptysBio to take stock. CEO Hamza Suria has left, bringing an end to his 11-year reign, and the board of directors is carrying out a strategic portfolio review of AnaptysBio’s three wholly owned clinical-phase programs.

read more

Sponsored: Bridging the preclinical to clinical divide: practical considerations for biomarker success

To successfully advance preclinical biomarker assays from the bench to the bedside, it is crucial to develop a clear plan for delivering assays that can be used within the clinical trial setting. Learn strategies for assessing and optimizing biomarker feasibility and utility to support study success.

read more

Bayer-backed Affini-T snags $175M to enter increasingly crowded KRAS-cancer field

Affini-T Therapeutics CEO Jak Knowles, M.D., is no stranger to the kind of startups that draw early capital, having once been vice president of venture investments for Bayer’s VC arm, Leaps by Bayer. But now, he’s the one asking for money, and his former employer is ready to dole it out.  

read more

Sponsored: Unlocking the power of AI-driven pathology in drug development: An Interview with Bristol Myers Squibb

Learn how Bristol Myers Squibb is unlocking new insights in translational research and development by transforming pathology with artificial intelligence

read more

Aligos hacks off 2nd hep B med since January after 'unexpected' reaction in 4 patients

Aligos Therapeutics has ended development of its second med since January after four patients fell ill in a phase 1 trial testing its treatment for chronic hepatitis B, including one person who was hospitalized. As a result, the company is pivoting its pipeline to focus on small-molecule therapies.

read more

ORIC walks away from lead cancer resistance program after lackluster phase 1b data

ORIC Pharmaceuticals is walking away from the lead program used to underpin its 2020 IPO after the cancer med did not demonstrate adequate clinical activity in several early-stage trials.

read more

An mRNA therapy improves breast cancer response to immunotherapy in mice

A team of scientists in Spain has discovered a promising approach to increasing immunotherapy's effectiveness in triple-negative breast cancer by targeting cancer stem cells. The researchers created a mRNA therapy prototype based on the findings and showed promising results in mice.

read more

Virtual clinical trials market worth $8B as CROs rush to add decentralized capabilities

Clinical trials are going virtual at a rapid clip after the COVID-19 pandemic, and Medi-Tech Insights says the market is now worth nearly $8 billion.

read more

Merck, building on Keytruda’s landmark biomarker nod, pressures GSK's limited I-O position with new FDA approval

Following a historic biomarker-driven FDA approval in 2017, Merck's Keytruda has expanded its label in one cancer subtype with that genetic abnormality, further pressuring GlaxoSmithKline's latecomer Jemperli.

read more

MIT, Mass General researchers develop handheld robot for tapping into blood vessels

The system uses an artificial intelligence-powered ultrasound scanner to guide needles and catheter hardware, to help stem severe bleeding or deliver fluids and medications all while potentially in the back of an ambulance.

read more

#FierceMadness: Grab a bracket and help us determine healthcare's biggest power broker!

This year, Fierce Healthcare's #FierceMadness is back, and we want you to help us identify the industry's most influential person.

read more

As rivals eye 'unjustified royalties,' Pfizer partner sues to defend COVID-19 shot Comirnaty

Pfizer has already reeled in tens of billions of dollars in sales for its COVID-19 shot Comirnaty. Now, one of the company's partners says rival companies are eyeing "hundreds of millions, if not billions, of dollars in unjustified royalties" through a potential patent lawsuit.

read more

Study: Rural hospital closures over latest decade affected more Black and Hispanic residents

A new study found rural hospital closures from 2010 to 2020 affected a larger share of Black and Hispanic residents compared with prior decades.

read more

Resources

Industry Report: The Top Four Barriers to Successful KOL Engagement

Read why many MSLs are still challenged in developing integrated strategies to increase the volume of meaningful engagements. Download this industry report to find out what the top challenges are and suggestion strategies to solve them. Download now.

eBook: Leveraging Clinical Data for Study Success

The landscape of clinical trials has been permanently changed. Today's trials require sponsors to modernize their use of technology and data to adapt. This eBook provides an overview of how sponsors can empower trials with real-time performance data to improve study integrity, reduce risks, optimize patient safety, and increase trial success rates.

Whitepaper: Autologous CAR T-Cell Manufacturing: Semiautomatic, Closed, Modular Workflow

Learn how to navigate the top manufacturing challenges and achieve a seamless transition from discovery to clinical manufacturing across the CAR T-cell therapy workflow.

eBook: EMEA Regulatory Roadblocks around Decentralized Trials

Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research.

Whitepaper: Top 5 Challenges Of Decentralized Clinical Trials And How To Overcome Them

How to overcome top challenges faced in decentralized trials.

Paid Marketplace: United Cargo: Providing comprehensive solutions for the most critical shipments

The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now.

Whitepaper: Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Whitepaper: Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

Whitepaper: The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Events